Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
In brief
RATIONALE: Escitalopram may help improve depression and quality of life in patients with advanced lung or gastrointestinal cancer. It is not yet known whether escitalopram is more effective than a placebo in treating depression in patients with advanced lung or gastrointestinal cancer. PURPOSE: This randomized clinical trial is studying the side effects of escitalopram and to see how well it works compared to a placebo in treating depression in patients with advanced lung or gastrointestinal cancer.
Key facts
- Study ID
- NCT00387348
- Run by
- Massachusetts General Hospital
- People needed
- 24
- Starts
- 2006-03-01
- Expected to finish
- 2011-04-01
- Last updated by the study team
- 2012-12-03
Who can join
Age: 35 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.